Baird analyst Brian Skorney raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $112 from $95 and keeps an Outperform rating on the shares. The firm updated its model following Ph 2b HDV data which reinforces the value of its Bluejay acquisition.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MIRM:
- Mirum Pharmaceuticals price target raised to $150 from $130 at H.C. Wainwright
- Mirum’s brelovitug succeeds in Phase 2b HDV trial
- Mirum announces primary endpoint met in Phase 2b portion of AZURE-1 study
- Mirum Therapeutics: Favorable Risk/Reward Ahead of Key 2Q26 VISTAS Readout for Volixibat in PSC
- Mirum Pharmaceuticals price target raised to $125 from $117 at TD Cowen